Jacobson Robert M, Grill Diane E, Oberg Ann L, Tosh Pritish K, Ovsyannikova Inna G, Poland Gregory A
a Vaccine Research Group; Mayo Clinic ; Rochester , MN USA.
Hum Vaccin Immunother. 2015;11(4):961-9. doi: 10.1080/21645515.2015.1011990.
To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination. Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs. Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35% overall had at least a 4-fold increase by Day 28. Of these 37, 3 waned at least 4-fold, and 13 others 2-fold. Thus 15% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not. HI titers at Days 0, 28, and 75 populate 4 biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.
通过检测接种疫苗后长达75天的甲型H1N1流感血凝抑制(HI)效价,来确定50至74岁成年人中不同的抗体谱。50至74岁的健康受试者接种了2010 - 2011年三价灭活流感疫苗。我们在第0天、第28天和第75天采集静脉样本,检测HI、病毒中和抗体(VNA)以及B细胞酶联免疫斑点试验(ELISPOT)。在106名受试者中,对于接种前HI效价为1:640的人群,HI效价显示出上限效应,接种后没有受试者效价升高,比例为11%或10%。在其余95名受试者中,到第28天总体上只有37%或35%的人至少有4倍的效价增长。在这37人中,3人效价至少下降了4倍,另外13人下降了2倍。因此,到第75天,15%的受试者抗体效价出现下降。超过一半的人根本没有反应。根据HI定义的这些受试者的抗体谱不随年龄或性别而变化。VNA结果与HI谱相似,但B细胞ELISPOT的谱不同。第0天、第28天和第75天的HI效价形成了4种生物学上合理的谱。局限性包括在操作上定义抗体效价下降以及明显的上限缺乏共识。此外,尽管HI作为疫苗反应的标志物被广泛接受,但设定HI阈值存在局限性。然而,VNA在形成这些谱方面与HI密切匹配。因此,我们认为这些具有表面效度和内容效度的谱,可能为理解该年龄组对流感疫苗的基因组和转录组反应的差异提供基础。